Reflux treatment among medicines added to PBS Medication for a host of conditions will be newly subsidised from October, potentially generating $130 million in out-of-pocket savings.
Potentially ‘life changing’ arthritis drug listed on PBS Tofacitinib will be listed despite lingering concerns related to an increased risk of blood clots and potentially death when taken in high doses.
Important psoriatic arthritis drug listed on the PBS Ixekizumab is available for patients with the life-long condition, which causes joints to become stiff, painful and often swollen.